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Trial DesignRationale and design of the Clinical Evaluation
of Magnetic Resonance Imaging in Coronary
heartdisease2 trial (CE-MARC2):Aprospective,
multicenter, randomized trial of diagnostic
strategies in suspected coronary heart disease
David P. Ripley, BSc, MBChB, a Julia M. Brown, MSc, b Colin C. Everett, MSc, b Petra Bijsterveld, MA, a Simon
Walker, MSc, MA, c Mark Sculpher, PhD, c Gerry P. McCann, MBChB, MD, d Colin Berry, MBChB, PhD, e Sven Plein,
MD, PhD, a and John P. Greenwood, MBChB, PhD a Leeds, York, Leicester, and Glasgow, UKBackground A number of investigative strategies exist for the diagnosis of coronary heart disease (CHD). Despite the
widespread availability of noninvasive imaging, invasive angiography is commonly used early in the diagnostic pathway.
Consequently, approximately 60% of angiograms reveal no evidence of obstructive coronary disease. Reducing unnecessary
angiography has potential financial savings and avoids exposing the patient to unnecessary risk. There are no large-scale
comparative effectiveness trials of the different diagnostic strategies recommended in international guidelines and none that
have evaluated the safety and efficacy of cardiovascular magnetic resonance.
Trial Design CE-MARC 2 is a prospective, multicenter, 3-arm parallel group, randomized controlled trial of patients with
suspected CHD (pretest likelihood 10%-90%) requiring further investigation. A total of 1,200 patients will be randomized on a
2:2:1 basis to receive 3.0-T cardiovascular magnetic resonance–guided care, single-photon emission computed tomography–
guided care (according to American College of Cardiology/American Heart Association appropriate-use criteria), or National
Institute for Health and Care Excellence guidelines–based management. The primary (efficacy) end point is the occurrence of
unnecessary angiography as defined by a normal (N0.8) invasive fractional flow reserve. Safety of each strategywill be assessedby
3-year major adverse cardiovascular event rates. Cost-effectiveness and health-related quality-of-life measures will be performed.
Conclusions The CE-MARC 2 trial will provide comparative efficacy and safety evidence for 3 different strategies of
investigating patients with suspected CHD, with the intension of reducing unnecessary invasive angiography rates. Evaluation
of these management strategies has the potential to improve patient care, health-related quality of life, and the cost-
effectiveness of CHD investigation. (Am Heart J 2015;169:17-24.e1.)Background
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http://dx.doi.org/10.1016/j.ahj.2014.10.008variety of investigations may be used to diagnose CHD, risk-
stratify, and determine the need for coronary revasculariza-
tion. Myocardial perfusion scintigraphy by single-photon
emission computed tomography (SPECT) is the most
commonly used test worldwide for the assessment of
myocardial ischemia, and there is a large body of evidence
to support its prognostic value. Cardiovascular magnetic
resonance (CMR) has high diagnostic accuracy for the
detection of CHD, and the CE-MARC study demonstrated
CMR's superiority over SPECT.1 Despite the widespread
availability and recommendation of noninvasive imaging
investigations in national and international guidelines,2–4
invasive coronary angiography is commonly used early in the
diagnostic pathway. Evidence from large populations of
patients presenting with chest pain has confirmed that the
majority will not have significant obstructive coronary
disease.5,6 In the United States, the American College of
Figure 1
CE-MARC 2 recruitment process. *PTL as defined by NICE (CG95) guidelines.3
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January 2015Cardiology National Cardiovascular Data Registry identified
almost 400,000 patients without known CHD that under-
went elective catheterization from January 2004 through
April 2008, and only 38% had obstructive CHD.6
Avoiding unnecessary angiography has potential finan-
cial savings and avoids exposing the patient to unneces-
sary risk. Invasive coronary angiography has a risk of
major complications of 1.7%. Furthermore, the dose and
stochastic effects of x-ray radiation are frequently mis-
judged,7 with the risk of developing a solid tumor estimated
at 1:2500 diagnostic coronary angiographic procedures.8
Paradoxically, the implementation of UK national guide-
lines for the assessment and diagnosis of recent onset chest
pain has been demonstrated to increase invasive coronary
angiography rates between 20% and 28%.9
A previous single-center trial (CECaT) indicated that
invasive angiography could be avoided in 20% to 25% of
patients using functional testing as an initial gatekeeper.10
To date, there are no large-scale comparative effective-
ness trials of the different diagnostic strategies recom-
mended in international guidelines and none that have
evaluated the safety and efficacy of CMR.Study objectives
The primary objectives are to determine if 3.0-T CMR-
guided management is superior to (a) National Institute for
Health and Care Excellence (NICE) guidelines–based man-
agement (CG95),3 and (b) SPECT-guided management,11 interms of reducing the rates of unnecessary invasive
angiography occurring within 12 months in patients with
a pretest likelihood (PTL) of CHD of 10% to 90%.
Secondary objectives will determine (a) if in patients
with a high PTL of CHD (61%-90%), noninvasive imaging
(CMR or SPECT) is superior to NICE guidelines–based
management, in terms of reducing the occurrence of
unnecessary invasive angiography; (b) safety in terms of
major adverse cardiovascular events (MACE) at 3 years
between the CMR-guided care group and those receiving
NICE guidelines–based management; (c) safety in terms
of MACE at 3 years between the CMR-guided care group
and those receiving SPECT-guided management; and
(d) cost-effectiveness and impact on health-related
quality-of-life (HRQoL) measures of a CMR-guided care
strategy compared with NICE guidelines–based manage-
ment and SPECT-guided management.Methods
Study design
CE-MARC 2 (clinicaltrials.gov: NCT01664858) is a
prospective, multicenter, multivendor, 3-arm parallel
group, randomized controlled trial of patients referred
to cardiology care for further evaluation of symptoms
thought to be angina pectoris. A total of 1,200 patients
with suspected CHD will be randomized on a 2:2:1 basis
to receive CMR-guided care, SPECT-guided care, or NICE
guidelines–based management (Figures 1 and 2).
Figure 2
CE-MARC 2 study flow diagram.
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Volume 169, Number 1Statistical analysis will be performed by the Clinical
Trials Research Unit, University of Leeds, and the Centre
for Health Economics, University of York. The study
population will be followed up prospectively for a
minimum of 3 years to establish long-term MACE in
each investigation arm. The study will be conducted in
accordance with the Declaration of Helsinki and has been
approved by the National Research Ethics Service.
Patient Population, Recruitment, and Randomization
Subjects will be considered for inclusion if they are
30 years or older presenting to participating hospitals
(Appendix A) with suspected cardiac chest pain (angina)
with a defined CHD PTL of 10% to 90%.3 Full inclusion and
exclusion criteria are listed in Table I. An anonymized log of
all patients screened for eligibility who are not recruited
either because they are ineligible or because they declined
to participate will be kept.
The treating clinicianmakes a clinical diagnosis of typical
angina if the patient has all 3 salient features of angina
(constricting discomfort in the front of the chest, or in the
neck, shoulders, jaw, or arms; precipitated by physical
exertion; and relieved by rest or glyceryl trinitrate within
~5minutes) or atypical angina if they have 2 of 3.3,12 Those
with one or none of the features are defined as nonanginal
chest pain3,12 and ineligible for the study. The patients' riskfactors (age, gender, ethnicity, abdominal and hip circum-
ference, lipid profile, blood pressure, smoking, and
diabetic status), medical history (including rheumatoid
arthritis, hypertension, hyperlipidemia, peripheral vascular
disease, and cerebrovascular disease), and family history of
premature CHD will be recorded.
Patients will undergo risk stratification with their PTL of
having CHD calculated3,13 and categorized as low (10%-
29%), intermediate (30%-60%), or high (61%-90%). Ran-
domization will be achieved using minimization, incorpo-
rating a random element through a computer-generated
program accessed via a 24-hour telephone service. Thiswill
allocate patients in a 2:2:1 ratio betweenCMR/SPECT/NICE
after taking account of the following stratification factors:
randomizing site, age (30-64 years, ≥65 years), PTL (10%-
29%, 30%-60%, 61%-90%), and gender. Those with low PTL
of underlying CHD (10%-29%) randomized to NICE
guidelines will undergo cardiac computed tomography
(CCT), intermediate PTL (30%-60%) SPECT, and high PTL
(61%-90%) coronary angiography.Funding
The trial was funded by the British Heart Foundation
(SP/12/1/29062). Additional support was received from
the Leeds Teaching Hospital Charitable Foundation and
Table I. Inclusion and exclusion criteria into the CE-MARC2 study
Inclusion criteria Exclusion eriteria
Age ≥30 y Nonanginal chest pain
Suspected stable angina (CHD)
that requires further investigation
Normal SPECT/CCT within the last 2 y
A defined PTL of 10%-90% Clinically unstable
Suitable for revascularization
if required
Previous MI or biomarker positive ACS
Previous revascularization with
coronary artery bypass surgery or PCI
Contraindication to CMR imaging
known adverse reaction to adenosine or
gadolinium/iodinated contrast agents
Obesity (where body girth
exceeds scanner diameter)
Pregnancy and/or breast-feeding
Known chronic renal failure (estimated
glomerular filtration rate
b30 mL/min per 1.73 m2)
Inability to give informed consent
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January 2015the National Institute for Health Research, through the
Local Clinical Research Networks.
The authors are solely responsible for the design and
conduct of this study, all study analyses, the drafting and
editing of the manuscript, and its final contents.
Investigation Details
Cardiovascular magnetic resonance. Cardiovascu-
lar magnetic resonance will be performed on a clinical
3.0-T scanner using protocols that conform to interna-
tional standards.14 A cardiac imaging receiver coil
configuration will be used, and electrocardiogram
(ECG) gating will be performed. The scan will comprise
the following:
1. Survey and reference scans prior to defining the
short, vertical long, and horizontal long axes
acquired with a balanced steady-state free preces-
sion (bSSFP), single-slice breath-hold sequence.
bSSFP pulse sequence parameters dependent on
scanner manufacturer and site. Typical parameters
are as follows: echo time 1.3 milliseconds, repeti-
tion time 2.6 milliseconds, flip angle 40°, field of
view 320-420 mm according to patient size, SENSE
or GRAPPA acceleration, slice thickness 10 mm,
and 30 phases per cardiac cycle.
2. Stress perfusion imaging performed with adenosine
administered initially at 140 μg kg−1 min−1. Adequate
hemodynamic response is assessed by either ≥10%
heart rate increase or ≥10 mm Hg decrease in
systolic blood pressure. If there is inadequate
hemodynamic response, then the dose will be
increased incrementally to 170 μg kg−1 min−1 and
then 210 μg kg−1 min−1 for a further 2 minutes until
hemodynamic response is achieved.Perfusion image acquisition will use a 2-dimensional,
T1-weighted saturation recovery–prepared gradient
echo-pulse sequence in 3 short-axis slices, planned
using the 3/5 technique,15 using either parallel
imaging acceleration (SENSE or GRAPPA) or spatio-
temporal undersampling (5× kt-BLAST). First-pass
contrast-enhanced study will be performed using a
dual-bolus technique (0.075 mmol/kg gadobutrol
[Gadovist; Bayer Schering Pharma, Berlin, Germany])
for the main bolus preceded by the same volume of a
10% dilute contrast agent dose for the prebolus, both
administered at a rate of 4.0mL/s followed by a 20-mL
saline flush.
3. Resting wall motion and left ventricular function will
be assessed with a contiguous stack of multiphase
ventricular short-axis bSSFP cines (10-12 slices, 30
phases, 10-mm slice thickness, 0-mm gap, same cine
pulse sequence as above).
4. The restmyocardial perfusion studywill use identical
pulse sequence, slice positioning, and injection
characteristics to the stress perfusion scan. If the
stress perfusion scanwas not of adequate quality (eg,
ectopics and failure to trigger), a repeat stressmay be
performed as alternative to the rest study.
5. Late gadolinium enhancement (LGE) performed in
10 to 12 short-axis slices 10 to 15minutes after step 4
with an inversion recovery–prepared T1-weighted
gradient echo-pulse sequence. Typical parameters
are as follows: echo time 2.0 milliseconds, repetition
time 3.7 milliseconds, flip angle 25°, acquired spatial
resolution 0.70 × 0.70 × 10 mm3, and inversion time
individually adjusted according to inversion time
scout. LGE will be acquired with alternate heart beat
acquisition (with single-shot or navigated LGE, an
option for poor breath holders) and long-axis and
modified views acquired if clinically indicated.
Single-photon emission computed tomography.
Radionuclide imaging will be performed according to
local standard departmental practice conforming to both
national and international guidelines.16–18 Patients will
undergo either a 1- or 2-day scanning protocol with a
radioisotope tracer 99mTc-tetrofosmin or 99mTc-sestamibi
(Myoview, GE Healthcare and CARDIOLITE, Lantheus
Medical Imaging). A weight-adjusted dose up to a
maximum of 1000 MBq per examination will be used
for stress and rest imaging, which will be performed
within 5 days of each other.
Stress examination will be performed with either
treadmill or bicycle exercise, pharmacologic vasodilator
stress (with adenosine or regadenoson), or a combina-
tion. Treadmill will involve exercise using the BRUCE or
modified BRUCE protocol or bicycle ergometer typical-
ly commencing at 25 W increasing workload by 25 W
every 2 minutes. Radioisotope tracer will be injected at
peak stress.
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Volume 169, Number 1If pharmacologic stress with adenosine is used, the
administration regimen will be comparable with the CMR
protocol. If regadenoson is used, 0.4 mg will be delivered
by rapid intravenous injection. Radioisotope tracer will
be injected after at least 4 minutes of adequate
hemodynamic/symptom response. Vasodilator stress
may be combined with submaximal exercise.
Images will be acquired on either a dual headed gamma
camera or solid-state cadmium zinc telluride camera. Stress
and rest images will be gated to the ECG, and attenuation
correction will be used where routinely available.
Cardiac CT. Cardiac computed tomography will be
performed on a minimum 64-slice multidetector CT and
follow international guidelines.19 Coronary artery calcium
(CAC) scoring scan protocol will involve the following:
1. Scout scans.
2. Unenhanced scan with prospective gating and
inspiratory breath-hold. A minimum scan length
(z-axis distance) will be used from tracheal
bifurcation to the inferior border of the heart.
3. Agatson CAC score will be calculated and NICE
guidance followed.3 If CAC is 0, no further imaging
will be performed; if CAC score is 1 to 400, proceed to
CT coronary angiography (CTCA); and if CAC score is
N400, refer for invasive coronary angiography.
For CT coronary angiography, heart rate control will be
achieved with β-blockade (intravenous or oral) and short-
acting sublingual nitrates given. Computed tomography
coronary angiography will be performed where possible,
with a prospective gating technique using the minimum
scan range planned from the unenhanced scan. Typical
scan parameters are as follows: 0.625-mm collimation,
pitch 0.2-0.4, 100-120 kV, and 400-830 mAs (adjusted
according to body mass index). If retrospective gating is
required, ECG dose modulation will be used to minimize
radiation dose. The acquisition window will usually be
centered at end-diastole (end-systole may be used at the
discretion of the attending physician). In those with
variable heart rates, time interval padding may be used to
allow reconstruction of both the systolic and diastolic
phase data sets. The exact scan parameters and radiation
reduction algorithms used will be dependent on the
hardware vendor. Iodinated contrast agent of 60 to 120mL
will be administered at a flow rate of 4.5 to 6.5 mL/s,
followed by a bolus of normal saline (eg, 50mL and 5mL/s)
during an acquisition with inspiratory breath-hold. Either a
test bolus or a bolus tracking technique may be used.
Invasive angiography and Fractional Flow Reserve.
Angiography will be performed using a standard technique
(radial or femoral approach). Fractional flow reserve (FFR)
(PressureWire; St Jude Medical, Minneapolis, MN) will be
performed in all vessels ≥2.5 mm with stenosis ≥40% and
≤90%, following intracoronary nitrates, using adenosine at
140 to 210 μg kg−1 min−1 to achieve maximal hyperemiaand hemodynamic steady state; pull-back assessment of
diffuse disease or serial stenoses can be made. Adenosine
will be administered as per CMR protocol. Totally occluded
coronary arteries will have a default FFR value of 0.50
recorded; for lesions N90%, FFR will also be considered
positive (0.50), and for lesions b40%, FFRwill be considered
normal (0.90).20 All sites will have FFR quality assurance
core laboratory assessment of the FFR recordings using
vendor software (RADIVIEW 2.2; St Jude Medical Corp).
Investigation reporting
All test results will be reported by independent
cardiology/radiology consultants with a minimum 5-year
experience in the imaging modality. In accordance with
usual clinical practice, all clinical data from all noninva-
sive imaging modalities will be available for the reporting
physician to make an overall clinical judgement.
Cardiovascular magnetic resonance. Cardiovascu-
lar magnetic resonance analysis will be both visual and
quantitative following international recommendations.21
Local on-site reporting will include regional wall motion
abnormalities (by visual analysis using the 17-segment
American Heart Association/American College of Cardiol-
ogy model). Each segment scored as 0 = normal, 1 = mild
hypokinesia, 2 = severe hypokinesia, 3 = akinesia, or 4 =
dyskinesia. Quantitative analysis will include the following:
end-diastolic volume (mL), end-systolic volume (mL),
stroke volume (mL), and ejection fraction (%).
Detection of hypoperfusion (ischemia), by visual compar-
isonof stress, rest, andLGE scans,will be scored as 0=normal,
1 = equivocal, 2 = nontransmural ischemia b50%, 3 =
nontransmural ischemia≥50%, or 4 = transmural ischemia
in 16 segments of the 17-segment American Heart
Association/American College of Cardiology model (ex-
cluding the apical cap).
Any infarct (scar)will be reportedbasedon the LGE images
(17-segment model), with scores of 0 = no hyperenhance-
ment, 1 = 1%-25% mural thickness, 2 = 26%-50%, 3 = 51%-
75%, or 4 = N75% allocated to each segment.
A positive result (≥2 adjacent segments [or 60° arc-
equivalent if the defect crosses segmental boundaries]
with ≥50% transmural extent of ischemia, scar, or
ischemia-scar combination) will by protocol necessitate
referral for invasive angiography ± FFR
Single-photon emission computed tomography.
Single-photon emission computed tomography analysis
will be both visual and quantitative. Local on-site re-
porting will include any regional wall motion abnormality
(by visual analysis using the 17-segment model). Each
segment scored as 0 = normal, 1 = mild hypokinesia, 2 =
severe hypokinesia, 3 = akinesia, or 4 = dyskinesia.
Evidence of ischemia, by visual comparison of rest and
stress scans,will be scored as 0 =normal, 1 =mild 51%-70%,
2 = moderate 31%-50%, 3 = severe 10%-30%, or 4 = absent
b10% in each segment. Quantitative analysis will include
summed rest score and summed stress scores, quantitative
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perfusion SPECT total perfusion deficit (%), end-systolic
volume (mL), end-diastolic volume (mL), stroke volume
(mL), and ejection fraction (%).
The presence of artifacts including subdiaphragmatic
activity affecting the inferior wall, significant patient
movement, anterior attenuation, inferior attenuation, and
left bundle-brunch block artifact will be recorded.
A positive result (summed stress score ≥ 4), unless
believed by the reporting clinician to represent attenu-
ation artifact, will by protocol necessitate referral for
invasive angiography ± FFR.
Cardiac CT. The total Agatson CAC score from the
unenhanced scanwill be determined. If theCAC score isN0
and b400, a contrast-enhanced scan will be performed.
Coronary stenosis will be graded as 0 = normal, 1 =
minimal b25% stenosis, 2 = mild 25%-49%, 3 = moderate
50%-69%, 4 = severe 70%-99%, or 5 = occluded 100%. A
positive result (either CAC N400 or any luminal stenosis
≥50% in an epicardial coronary artery ≥2.5-mm diameter)
will by protocol necessitate invasive angiography ± FFR.
X-ray angiography and FFR. Invasive x-ray angiog-
raphy will be interpreted visually by the performing
clinician recording the coronary artery dominance,
location, and visual degree (%) of all coronary stenoses
in all major epicardial coronary arteries (with luminal
diameter ≥2.5 mm). FFR measurement will be recorded
in all arteries ≥2.5 mm with a visually recorded diameter
stenosis ≥40% and ≤90%. Where FFR cannot be
performed due to clinical/safety reasons, quantitative
coronary angiography (QCA) will be performed using
validated commercial vendor software. In this instance,
QCA measurements will be made during offline analysis
by a single independent blinded observer at the
Glasgow Angiographic core laboratory. Lesions will be
considered significant if a coronary artery segment
(luminal diameter ≥2.5 mm) analyzed by QCA has a
percentage diameter stenosis of ≥70% in one view or
≥50% in 2 orthogonal views.
Protocol deviations
On occasion where the attending cardiologist overrules
the protocol requirement to proceed to invasive coronary
angiography, this will be recorded as a protocol violation.
Annual follow-up
Annual follow-up over the subsequent 3 years will be
undertaken to record death (including cause), other
MACE, and withdrawal. For alive patients, medical history
since randomization, including details and dates of acute
coronary syndrome (ACS), emergency or elective revas-
cularization procedure, any admission for cardiovascular
cause will be obtained and verified from hospital or
family practitioner records. Details of any recent
cardiovascular investigations will be taken. In addition,
Office for National Statistics monitoring will be soughtfor deceased patients to determine the certified causes
of death.
Primary end point
The primary end point is unnecessary invasive coronary
angiography occurring within 12 months in each arm.
This will be defined at the time of coronary angiography
by an FFRmeasurement of N0.80 in all vessels≥2.5 mm in
a patient-based analysis (ie, at least 1 vessel with an FFR
measurement of b0.8 will be required to define a patient
with disease).
An “unnecessary angiogram” will be defined as one of
the following:
• A negative FFR and positive noninvasive test result
(ie, a false-positive test result)
• A negative FFR in a high PTL (61%-90%) patient that
proceeds directly to invasive angiography in the
NICE guidelines–based strategy arm (ie, a false-positive
for the strategy)
• A negative FFR and a negative noninvasive test result
(ie, a true-negative strategy result in which the
imaging result was “not believed” by the treating
cardiologist—based on intention-to-treat principles)
• A negative FFR and an inconclusive noninvasive test
result in which angiography had to be performed to
make the diagnosis (ie, failure of the strategy to
produce a diagnosis)
Secondary end points
Major adverse cardiovascular events. For all
patients, MACE at 12 months and a minimum of 3 years
will be reported. Major adverse cardiovascular events will
be defined as death due to cardiovascular cause,
myocardial infarction (MI; defined by the Third Universal
Definition22), unplanned coronary revascularization, and
hospital admission for cardiovascular cause. Hospitali-
zation for cardiovascular cause will be defined as
troponin-negative ACS, spontaneous MI (type 1), MI
secondary to ischemic imbalance (type 2), MI related to
stent thrombosis (type 4b), arrhythmia, stroke, and
heart failure.
Positive coronary angiogram. The proportion of
patients in the relevant population who undergo an
invasive coronary angiogram yielding a positive finding by
FFRwithin 12months of randomizationwill be determined.
Economic evaluation. To assess the long-term cost-
effectiveness of the alternate diagnostic testing strategies,
information from the trial will be used to update the
economic model developed as part of the CE-MARC trial.23
The model will use information from the trial, including
resource use, costs, HRQoL, and other clinical outcomes
(eg, on unnecessary tests and MACE events), together with
epidemiologic, clinical, and economic data from other
sources to calculate costs and quality-adjusted life-years for
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Volume 169, Number 1patients. The economic evaluation will use methods
consistent with those recommended by NICE.24 Given
the potential difference between diagnostic strategies in
terms of mortality, the modeling will adopt a lifetime time
horizon to capture any difference.
Quality of life. Health-related quality of life will be
measured by the following:
- Seattle Angina Questionnaire–UK version
- Medical Outcomes Survey–Short Form 12
- EuroQol 5-Dimensions.
Complications. Complications directly related to
investigational or procedural aspects of the study
resulting in prolonged hospital stay/specific treatment
that would otherwise have not been required will be
reported. These will be established and adjudicated by
the Trial Steering Committee and Trial Management
Group and reported to the Data Monitoring and Ethics
Committee (DMEC).
Statistical considerations
Sample size. Sample size calculations were performed
using nQuery 7.0, Statistical Solutions Ltd., Cork, Ireland.
For the primary end point analyses, a sample size of 1,200
(allowing for 20% noncompletion) will provide 99% power
to detect a difference of unnecessary angiography rates
between CMR and NICE guidelines–based management—
accounting for the 2:1 allocation ratio—and 94% power
between CMR and SPECT-guided care (2-sided test 5%
significance level for a continuity-correctedχ2 test24). This
is based on projected unnecessary angiography rates of
4.5%, 11.7%, and 30% in the CMR, SPECT, and NICE arms,
respectively, arrived at by estimating the PTL profile of
CEMARC patients (we estimated the PTL distribution to be
10%:33%:57% for low/moderate/high PTL, for those
patients with PTL 10%-90%) and the false-positive rates
of CMR and SPECT in these subgroups to compute a
weighted average false-positive rate as the expected
unnecessary angiogram rate. For the NICE arm, we
noted that in patients with 61% to 90% PTL, nearly
60% of angiograms were negative, and so would drive
high rates for this strategy, despite CT and SPECT
patients (10%-60% PTL) undergoing fewer unneces-
sary angiograms.
Analysis plan. Statistical analysis will be performed as
agreed in the prespecified statistical analysis plan. All
analyses will be performed on intention-to-treat basis.
The primary end point will be performed after the 12-
month assessment has been completed by the last
patient entered into the study and a complete and
exhaustive data chase has been performed. Analyses of
primary and secondary end points will be performed
separately for the CMR-guided vs NICE-guided care,
CMR-guided vs SPECT-guided care, and SPECT-guided vs
NICE-guided care comparisons.Primary end point analysis. The difference in
proportions of patients randomized to each arm with a
study-defined unnecessary angiogram and 95%CI for this
difference will be presented for summary purposes. A
binary logistic regression will model the relative odds of
receiving an unnecessary angiogram for CMR-guided care
vs the group of interest (either NICE or SPECT-guided
care pathways) when controlling for the minimization
factors. The estimated odds ratios, 95% CI, and P values
will be presented. An unadjusted analysis will compare
the difference in the proportions between the 2 groups
using a χ2 test.
Secondary end point analysis
Major adverse cardiovascular events. The propor-
tions of patients in the 3 groups with a MACE at 12 and 36
months and absolute differences in these MACE rates will
be presented. This analysis will be performed both on the
intention-to-treat and per-protocol basis. Periprocedural
MI—type 4a (related to percutaneous coronary interven-
tion [PCI]) and type 5 (related to coronary artery bypass
grafting)—and planned revascularization (PCI or coro-
nary artery bypass grafting) based on the index FFR
results will be censored.
Quality of life. The scores will be presented for the
groups at 6, 12, 24, and 36 months. The scores for the
dimensions of the Seattle AnginaQuestionnaire andMedical
Outcomes Survey-Short Form 12 will be summarized by
randomized group at each time point. Multilevel repeated-
measures modeling will be used to estimate differences
between the groups at all postbaseline time points
(allowing for time, trial group, and trial group by time
interaction, and adjusting for baseline QoL and minimiza-
tion factors [all fixed effects], and for patient and patient by
time interaction [random effects]). Residuals and predicted
values produced from the multivariate models will be
examined to assess the assumptions of the statistical model.
Data monitoring
Data will be monitored for completeness and quality
by the Clinical Trials Research Unit. A full monitoring
schedule including serious adverse events and adverse
reactions will be established and agreed by the Trial
Steering Committee and Trial Management Group.
Ethical and safety considerations will be monitored by
the DMEC (Appendix B). A quality assurance process
will be undertaken centrally by independent modality-
specific imaging experts, to monitor the quality of
image acquisition and interpretation of each imaging
modality at all recruiting centers. This will involve an
initial review of the first 15 imaging studies followed by
an ongoing review of a random 10% of each imaging
modality at each participating site. Clinical interpreta-
tion of the individual components of each imaging
modality and overall study recommendation will be
scored as 1 (agreement), 2 (minor disagreement), or 3
24 Ripley et al
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independent consideration/action.Conclusion
The CE-MARC 2 trial is a prospective, multicenter, 3-
arm parallel group, randomized controlled trial; it will
provide comparative efficacy and safety evidence for 3
different strategies of investigating patients with sus-
pected CHD, with the intention of reducing unnecessary
invasive angiography rates. Evaluation of these manage-
ment strategies has the potential to improve patient care,
HRQoL, and the cost-effectiveness of CHD investigation.Disclosures
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Leeds General Infirmary, Leeds, UK (CI: Prof. J.P.
Greenwood, local PI: Prof. S. Plein).
Glenfield Hospital, Leicester, UK (PI: Dr G.P. McCann).
Greater Glasgow and Clyde Hospitals, UK (PI: Prof.
C. Berry).
John Radcliffe Hospital, Oxford, UK (PI: Dr E.
Dall'Armellina).
Bristol Royal Infirmary, Bristol, UK (PI: Dr C. Bucciarelli-
Ducci).
St George's Hospital, London, UK (PI: Prof. A. Prasad).Appendix B. Trial management structure
Trial Management Group: Prof. J.P. Greenwood (Chief
Investigator [Chair]), Prof. S. Plein (Co-investigator), Prof. C.
Berry (Co-investigator), Dr G.P. McCann (Co-investigator),
Prof. Mark Sculpher (Co-investigator), Dr D.P. Ripley(Clinical Research Fellow), Ms P. Bijsterveld (Senior
Research Nurse), Dr M. Bhogal (Senior Trial Co-ordinator),
Ms C. Reynolds (Data Manager), Prof. J. Brown (Supervising
Statistician), Mr C. Everett (Statistician), and Ms S. Hartley
(Trial Manager).
Trial Steering Committee: Independent members
comprise Professor A.L. Clark (Chair), Prof. A. Kelion
(SPECT expert), Dr C. Peebles (CCT expert), Dr S.
Wheatcroft (Interventionist), Dr M. Kelly (Independent
Statistician), and Mr G. Oliver (patient support group
representative). In addition, members of the Trial
Management Group include Prof. J.P. Greenwood,
Dr D.P. Ripley, Ms P. Bijsterveld, Dr M. Bhogal, Ms C.
Reynolds, Prof. J. Brown, Mr C. Everett, and Ms S. Hartley.
Data Monitoring and Ethics Committee: Professor J.J.
Deeks (Independent Chair), Dr J. Gunn (Independent
member), Dr N. Maredia (Independent member), and
Dr D. Blackman (Independent member).
